Beyond the label: real-world gastrointestinal adverse events associated with vedolizumab – a decade of FAERS pharmacovigilance
Jenseits des Labels: reale gastrointestinale unerwünschte Ereignisse unter Vedolizumab – ein Jahrzehnt FAERS-Pharmakovigilanz
Frontiers in Pharmacology · 14.01.2026 · 16
DOI: 10.3389/fphar.2025.1700820 ↗Auf einen Blick
Eine FAERS-Analyse identifizierte 95 signifikante gastrointestinale AE unter Vedolizumab; viele waren nicht im aktuellen Arzneimittel-Label genannt. Die meisten Meldungen waren schwerwiegend.
Fragestellung
Wie häufig und mit welchen Merkmalen werden gastrointestinale unerwünschte Ereignisse unter Vedolizumab in FAERS berichtet?
Methode
Analyse von 59.976 Vedolizumab-bezogenen Einzelfallberichten aus FAERS von Q1 2014 bis Q4 2024; Disproportionalitätsanalyse mit ROR, Deskription, TTO-Analyse und klinischer Relevanzbewertung.
Ergebnisse
17.943 Nennungen gastrointestinaler AE wurden eingeschlossen. 95 signifikante PTs; häufige Signale waren Diarrhö, abdominale Schmerzen, Hämatochezie und häufige Stuhlentleerungen. 70/95 (73,7 %) standen nicht im Label.
Einschränkungen
Daten aus Spontanmeldungen; bei Erwachsenen kann ein Datenvollständigkeits-Bias die Schwereverteilung beeinflusst haben.
Schlussfolgerung der Autor:innen
Die Analyse identifiziert bekannte und viele zuvor untererkannte gastrointestinale AE unter Vedolizumab. Die hohe Rate schwerwiegender Ereignisse spricht für erhöhte klinische Wachsamkeit und gezieltes Monitoring.
Kernaussagen
- 95 signifikante gastrointestinale PTs unter Vedolizumab
- 70/95 (73,7 %) nicht im aktuellen Label genannt
- Medianer Zeitpunkt bis zum Auftreten: 190 Tage
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 14.01.2026. Verfasst von Jianhong Zheng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Xinglin Hospital of Xiamen, Xinglin Branch of the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen …. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Vedolizumab is a gut-selective biologic widely used for inflammatory bowel disease (IBD). While randomized controlled trials (RCTs) provide initial safety profiles, real-world pharmacovigilance data are crucial for identifying a broader spectrum of adverse events (AEs), including rare or underrecognized associations. This study aimed to comprehensively characterize the real-world reporting frequency and characteristics of gastrointestinal AEs associated with vedolizumab using spontaneous reporting data.
Methods
We analyzed 59,976 vedolizumab-related individual case safety reports from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) database, covering the period from Q1 2014 to Q4 2024. After meticulous exclusion of IBD diagnostic terms, 17,943 mentions of vedolizumab-associated gastrointestinal AEs were included. Disproportionality analysis, employing reporting odds ratios (ROR) with a threshold of ≥20 cases and a 95% confidence interval lower bound >1, was performed to detect significant signals. Descriptive analyses, time-to-onset (TTO) analysis, and a semi-quantitative clinical relevance assessment system were also utilized.
Results
Disproportionality analysis identified 95 significant gastrointestinal AE preferred terms (PTs). Common and strongly signaled events included diarrhea, abdominal pain, haematochezia, and frequent bowel movements. Notably, 70 of these 95 significant PTs (73.7%) are not explicitly listed in the current vedolizumab drug label, suggesting potential novel or underrecognized associations. Most reported AEs were serious (90.09%). Analysis of demographic data revealed significant differences in the proportion of serious reports across gender, weight, and age groups. Males (91.44%) and patients in the <50 kg group (87.30%) had higher proportions of serious reports. Notably, adult patients (18∼65 years) showed a higher proportion of serious outcomes compared to pediatric and elderly groups, although this finding may be influenced by data completeness bias. The median time-to-onset for gastrointestinal AEs was 190 days.
Conclusion
This comprehensive real-world FAERS analysis identifies both known and a substantial number of previously underrecognized gastrointestinal AEs associated with vedolizumab. The high proportion of serious events, particularly observed in male patients and those with lower body weight, underscores the need for enhanced clinical vigilance and targeted monitoring, especially early in the treatment course. These hypothesis-generating findings warrant further validation through dedicated clinical studies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Xinglin Hospital of Xiamen, Xinglin Branch of the First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
- Drug Clinical Trial Institution & Department of Pharmacy, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.
Zitieren
APA
Zheng, J., Qiu, C., & Zhang, Z. (2026). Beyond the label: real-world gastrointestinal adverse events associated with vedolizumab – a decade of FAERS pharmacovigilance. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1700820
Vancouver
Zheng J, Qiu C, Zhang Z. Beyond the label: real-world gastrointestinal adverse events associated with vedolizumab – a decade of FAERS pharmacovigilance. Frontiers in Pharmacology. 2026;16. doi:10.3389/fphar.2025.1700820
BibTeX
@article{Zheng2026,
author = {Zheng, Jianhong and Qiu, Chunfeng and Zhang, Zhen},
title = {Beyond the label: real-world gastrointestinal adverse events associated with vedolizumab – a decade of FAERS pharmacovigilance},
journal = {Frontiers in Pharmacology},
year = {2026},
volume = {16},
doi = {10.3389/fphar.2025.1700820}
}
EUVIMED